Year |
Citation |
Score |
2021 |
Wang H, Brown PC, Chow ECY, Ewart L, Ferguson SS, Fitzpatrick S, Freedman BS, Guo GL, Hedrich W, Heyward S, Hickman J, Isoherranen N, Li AP, Liu Q, Mumenthaler SM, et al. 3D Cell Culture Models: Drug Pharmacokinetics, Safety Assessment, and Regulatory Consideration. Clinical and Translational Science. PMID 33982436 DOI: 10.1111/cts.13066 |
0.337 |
|
2021 |
Hedrich WD, Wang H. Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection. Pharmaceutical Research. PMID 33619640 DOI: 10.1007/s11095-021-02997-y |
0.34 |
|
2019 |
Liang D, Li L, Lynch C, Mackowiak B, Hedrich WD, Ai Y, Yin Y, Heyward S, Xia M, Wang H, Xue F. Human constitutive androstane receptor agonist DL5016: A novel sensitizer for cyclophosphamide-based chemotherapies. European Journal of Medicinal Chemistry. 179: 84-99. PMID 31247375 DOI: 10.1016/J.Ejmech.2019.06.031 |
0.388 |
|
2017 |
Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. Clinical Pharmacokinetics. PMID 29188435 DOI: 10.1007/S40262-017-0619-0 |
0.564 |
|
2017 |
Andar AU, Karan R, Pecher WT, DasSarma P, Hedrich WD, Stinchcomb AL, DasSarma S. Microneedle-Assisted Skin Permeation by Non-toxic Bioengineerable Gas Vesicle Nanoparticles. Molecular Pharmaceutics. PMID 28068767 DOI: 10.1021/Acs.Molpharmaceut.6B00859 |
0.346 |
|
2016 |
Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharmaceutica Sinica. B. 6: 413-425. PMID 27709010 DOI: 10.1016/J.Apsb.2016.07.016 |
0.599 |
|
2016 |
Hedrich WD, Xiao J, Heyward S, Zhang Y, Zhang J, Baer MR, Hassan HE, Wang H. Activation of the constitutive androstane receptor increases the therapeutic index of CHOP in lymphoma treatment. Molecular Cancer Therapeutics. PMID 26823489 DOI: 10.1158/1535-7163.Mct-15-0667 |
0.561 |
|
2015 |
Gharavi R, Hedrich W, Wang H, Hassan HE. Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions. Pharmaceutical Research. 32: 2477-502. PMID 25972096 DOI: 10.1007/S11095-015-1711-5 |
0.56 |
|
Show low-probability matches. |